{{Drugbox
| verifiedrevid = 437186133
| IUPAC_name = 1-tert-butyl-4,4-diphenylpiperidine<ref>Martndale: The Complete Drug Reference, 35th Ed.</ref>
| image = Budipine.svg

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|budipine}}
| pregnancy_category =  
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 57982-78-2
| ATC_prefix = N04
| ATC_suffix = BX03
| PubChem = 68778
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 62021
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = L9026OPI2Z
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07306
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 334491

<!--Chemical data-->
| C=21 | H=27 | N=1 
| molecular_weight = 293.446 g/mol
| smiles = c1(ccccc1)C3(c2ccccc2)CCN(C(C)(C)C)CC3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C21H27N/c1-20(2,3)22-16-14-21(15-17-22,18-10-6-4-7-11-18)19-12-8-5-9-13-19/h4-13H,14-17H2,1-3H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = QIHLUZAFSSMXHQ-UHFFFAOYSA-N
}}

'''Budipine''' (brand name '''Parkinsan''') is an [[antiparkinson agent]] marketed for the treatment of [[Parkinson's disease]].<ref name=Reichmann_2006>{{cite journal | url=http://www.jns-journal.com/article/S0022-510X%2806%2900235-8/abstract | title=Budipine in Parkinson's tremor. | author=Heinz Reichmann | journal=Journal of the Neurological Sciences |date=October 2006  | volume=248 | issue=1-2 | pages=53–55 | doi=10.1016/j.jns.2006.05.039 | pmid=16784759}}</ref><ref>{{cite journal | url=https://link.springer.com/chapter/10.1007%2F978-3-7091-6360-3_3 | title=Clinical efficacy of budipine in Parkinson's disease. | author=H. Przuntek | author2=T. Müller | journal=Journal of Neural Transmission. Supplementa | year=1999 | volume=56 | pages=75–82 | doi=10.1007/978-3-7091-6360-3_3 | pmid=10370903}}</ref>[http://adisinsight.springer.com/drugs/800003459]

While its exact [[mechanism of action]] is not well characterized,<ref name="Reichmann_2006"/> it is believed to be an [[NMDA receptor antagonist]],<ref>J. Kornhuber, B. Herr, J. Thome, P. Riederer. "The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue". J.Neural Transm.Suppl. 46:127-133, 1995. {{PMID|8821048}}</ref><ref>{{cite journal | url=http://www.eurekaselect.com/65015/article | title=Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. | author=Gene C. Palmer | journal=Current Drug Targets |date=September 2001  | volume=2 | issue=3 | pages=241–271 | doi=10.2174/1389450013348335 | pmid=11554551}}</ref> but also promoting the synthesis of [[dopamine]].<ref name="Przuntek_2002"/>

Because it provides additional benefits relative to existing treatments, it probably does not precisely mimic the mechanism of an existing known treatment.<ref name="Przuntek_2002">{{cite journal |vauthors=Przuntek H, Bittkau S, Bliesath H |title=Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen |journal=Arch. Neurol. |volume=59 |issue=5 |pages=803–6 |date=May 2002 |pmid=12020263 |doi= 10.1001/archneur.59.5.803|url=http://archneur.ama-assn.org/cgi/pmidlookup?view=long&pmid=12020263|display-authors=etal}}</ref><ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/S0006899306021494 | title=Effects of amantadine and budipine on antidepressant drug-evoked changes in extracellular dopamine in the frontal cortex of freely moving rats. | author=Jenny C.E. Owen | author2=Peter S. Whitton | journal=Brain Research |date=October 2006  | volume=1117 | issue=1 | pages=206–212 | doi=10.1016/j.brainres.2006.07.039 | pmid=16996043}}</ref>

==See also==
* [[AD-1211]]
* [[Delucemine]]
* [[Diphenidine]]
* [[Ephenidine]]
* [[Fluorolintane]]
* [[Lanicemine]]
* [[Methoxphenidine]] (MXP)
* [[MT-45]]
* [[Remacemide]]

==References==
{{Reflist|2}}

{{Antiparkinson}}
{{Ionotropic glutamate receptor modulators}}

[[Category:Antiparkinsonian agents]]
[[Category:Drugs with unknown mechanisms of action]]
[[Category:Piperidines]]
[[Category:Tert-butyl compounds]]


{{nervous-system-drug-stub}}